SCHOTT Pharma AG & Co. KGaA : Strong share price performance limits upside potential
>Strong DDS segment more than offset destocking effect for vials - SCHOTT Pharma published financial results for its FY 2023 (ending 30 Sept 2023), which confirmed prel. results, reported on 19 December (revenue of € 899m +9.4%; EBITDA of € 239m +8.6%; share of High Value Solutions (HVS) 48% + 900bp). Net earnings of € 152m (+20%) came in 7% above consensus and 2% above our estimate. This was predominantly driven by a lower-than-expected tax rate of 18% vs our estimat...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.